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Metastatic biomarkers in synovial sarcoma
Rosalia de Necochea-Campion1, Lee M. Zuckerman2, Hamid R. Mirshahidi3, Shahrzad Khosrowpour4,
Chien-Shing Chen1,3 and Saied Mirshahidi1*
Abstract
Synovial sarcoma (SS) is an aggressive soft tissue sarcoma (STS) that typically occurs in the extremities near a joint.
Metastatic disease is common and usually occurs in the lungs and lymph nodes. Surgical management is the
mainstay of treatment with chemotherapy and radiation typically used as adjuvant treatment. Although chemotherapy
has a positive impact on survival, the prognosis is poor if metastatic disease occurs. The biology of sarcoma invasion
and metastasis remain poorly understood. Chromosomal translocation with fusion of the SYT and SSX genes has been
described and is currently used as a diagnostic marker, although the full impact of the fusion is unknown. Multiple
biomarkers have been found to be associated with SS and are currently under investigation regarding their pathways
and mechanisms of action. Further research is needed in order to develop better diagnostic screening tools and
understanding of tumor behavior. Development of targeted therapies that reduce metastatic events in SS, would
dramatically improve patient prognosis.
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Background
Synovial sarcoma (SS) is the fourth most common type
of soft tissue sarcoma (STS) and accounts for 5–10% of
all soft tissue sarcomas [1]. SS was originally described
by Simon in 1865, and given the name “synovial sar-
coma” by Sabrazes et al. in 1934 based on a similar ap-
pearance to developing synovial tissue under light
microscopy [2]. SS has a tendency to arise in the soft tis-
sue surrounding larger joints, but it does not have a syn-
ovial cell origin [3]. While the exact cellular origin is an
ongoing topic of investigation, it is likely to arise from
undifferentiated mesenchymal stem cells [4]. Compared
with other soft tissue sarcomas, SS occurs predomin-
antly in younger adults with a median age of diagnosis
of 35 years [5]. The most common tumor location is in
the extremities, where approximately 70% of these tu-
mors develop [6], and these patients have significantly
better long term survival outcomes than those with non-
extremity involvement [7]. In patients with localized dis-
ease, 10 year survival outcomes vary from 8 to 88% de-
pending on tumor size and location [8]. Standard
treatment for synovial sarcoma is tumor resection
frequently accompanied by radiotherapy and/or chemo-
therapy, although some data suggests that therapies in
addition to surgery substantially increase long-term
metastatic risks [7].
Metastasis negatively impacts patient prognosis and
significantly reduces survival outcomes [9]. For pa-
tients who present with or develop metastatic tumors
median survival outcomes vary from 7 to 37 months
depending on lymph node involvement and meta-
static location [10]. SS can evolve slowly and there is
a high incidence of late metastasis which occurs in
about 50% of all cases [7]. Most metastatic tumors
develop in the lungs (80%), although bone (9.9%) and
liver (4.5%) are the next most frequent locations [9].
Synovial sarcoma can metastasize through the lymph
nodes with clinically detectable disease found in 15–
20% of newly diagnosed patients [11]. Histologically,
synovial sarcoma is classified into four subtypes con-
sisting of a biphasic (BPSS), monophasic fibrous or
monophasic epithelial (MPSS), and poorly differenti-
ated (PDSS, round cell) tumor cells [1]. While these
histological subtypes do not seem to be associated
with metastatic events [7, 12], they have been linked
to survival. A study of 3756 SS patients registered in
the National Cancer Data Base from 1998 to 2010
showed a significant difference in average 5-year
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survival numbers among patients with biphasic
(65%), monophasic (56%) and undifferentiated (52%)
tumors [13].
While many factors that influence synovial sarcoma
patient outcome have been identified, tumor behavior
remains highly unpredictable [14]. An extremely high
level of metastasis means that further studies are needed
to characterize the mechanisms that influence tumor ac-
tion. Ultimately, the identification of highly relevant mo-
lecular biomarkers associated with metastatic outcomes
and patient prognosis establishes the foundation for de-
velopment of better therapeutic strategies to target these
oncogenic factors. Several metastatic biomarkers that
have been described to date are described in the follow-
ing sections and summarized in Fig. 1.
Significance of the syt-ssx fusion gene
The chromosomal translocation t(X;18)(p11.2;q11.2)
fuses the SS18 (SYT) gene to the SSX gene (predomin-
antly SSX1 or SSX2) and is regarded as a founding event
in the oncogenic development of synovial sarcoma [15].
Yet, the exact transformative event of the chimeric SYT-
SSX gene product has not been fully elucidated. It has
been shown that SYT-SSX can interfere with assembly
of BAF (BRG-/BRM-associated factor) complexes affect-
ing the integration of a tumor suppressor component
and consequent SRY (sex-determining region Y)-box 2
(SOX2) activation which stimulates cell proliferation
[16]. Over 95% of SS can be characterized by expression
of the SYT-SSX gene and it is used as a routine diagnos-
tic marker for this type of cancer [15]. Although both
SYT and SSX proteins contain transcriptional regulation
domains, they lack any DNA binding regions, so their
regulatory effects are surmised to occur through interac-
tions with other proteins [17]. Accordingly, the SYT-SSX
fusion oncogene has been shown to interact with several
major epigenetic regulators as well as other DNA bind-
ing proteins and exert both direct and indirect effects on
transcript regulation [17, 18]. Of note, SYT-SSX has
been shown to act as a scaffold linking two master tran-
scription regulators TLE1 (transducin like enhancer of
split 1) and ATF2 (activating transcription factor 2) such
that TLE1 acts as a repressor of ATF2 target genes regu-
lating cell cycle, apoptosis, and more, demonstrating that
the SYT-SSX/TLE1/ATF2 complex is important not only
to oncogenic transformation but also tumor cell survival
Fig. 1 Schematic diagram summarizing functional relevance of metastatic signals in synovial sarcoma. SYT-SSX fusion is a founding event in the
development of this cancer which frequently results in the production of molecular signals that promote tumor metastasis. Abbreviations: Akt
(Serine/threonine kinase); CDCA2 (Cell division cycle A2); CXCR (Chemokine receptor); ERK1/2 (Extracellular signal-regulated kinase 1/2); EZH2
(Enhancer of zeste homologue 2); IGFBP7 (Insulin-like growth factor-binding protein-7); IGR (Insulin like growth factor receptor); KIF14 (Kinesin
family member 14); MAPK (Mitogen-activated protein kinases); MicroRNAs (miRNAs); MMPs (Matrix metalloproteinases); mTOR (Mammalian target
of rapamycin); NY-ESO-1 (New York esophageal squamous cell carcinoma 1); PI3K (Phosphatidylinositol-3-kinase); pri-miRNA (primary microRNA);
pre-miRNA (precursor microRNA); PKB (Protein kinase B); RAS (Ras GTPase); SCRN1 (Secernin-1); TGF-β (Transforming growth factor beta); TβR
(TGF-beta receptor); TF (transcription factor)
de Necochea-Campion et al. Biomarker Research  (2017) 5:4 Page 2 of 8
[19]. TLE has emerged as a useful diagnostic marker of
SS with robust expression detected in approximately
95% of these tumors however a low level of positive
staining in non-SS tumors indicates that this antibody
should only be used in a panel with other antibodies to
confirm diagnosis [20]. Recently, a highly specific assay
to detect the association of SYT-SSX and TLE in either
localized or metastatic SS tumors was developed and
shown to be useful in drug discovery assays seeking to
disrupt this interaction [21].
A number of studies have investigated the association
between SYT-SSX gene fusion type and metastatic risk.
Some have reported that the SYT-SSX1 fusion approxi-
mately doubles the risk of metastatic tumor develop-
ment compared with SYT-SSX2 [22, 23]. Intriguingly, a
similar pattern was evident in a survival study demon-
strating a median survival of 6.1 years for SS patients
with an SYT-SSX1 fusion gene compared with 13.7 years
for those with SYT-SSX2 [24]. In contrast, several other
studies report no significant associations between SYT-
SSX fusion type and metastasis or survival [7, 25]. These
conflicting data appear to suggest that the influence of
unspecified additional factors have a much larger role in
determining metastatic outcomes. These clinicopatho-
logical characteristics must be better defined to under-
stand in which context SYT-SSX has an important
versus an inconsequential role.
Circulating biomarkers
Development of a diagnostic blood test to detect SS and
assess metastatic risk would be a valuable tool for the
management of this disease. A whole blood microRNA
signature shows that SS patients demonstrate significant
upregulation of seven microRNAs (miR-99a-5p, miR-
146b-5p, miR-148b-3p, miR-195-5p, miR-223-3p, miR-
500b-3p and miR-505-3p) compared with patients in
remission and healthy controls [26]. Furthermore, ex-
pression levels of these seven microRNAs are signifi-
cantly reduced by 5–50 fold increments after local
tumor resection, but once again dramatically upregu-
lated if a patient develops recurrent local or metastatic
disease [26]. Thus, since a clearly defined microRNA ex-
pression panel can be used to distinguish SS from other
malignancies as well as characterize metastatic and re-
current tumor status, this method could be useful in
therapeutic monitoring of patients [26]. miRNAs have a
critical role in activation of the Ras GTPase/Mitogen-ac-
tivated protein kinases (Ras/MAPK) pathway necessary
for tumor development [27], and miRNA suppression
significantly inhibits SS cell proliferation in vitro [28].
Detection of a circulating SYT-SSX fusion gene prod-
uct could be another important method for assessing
metastatic risk in patients with SS. In culture, it has been
shown that SS cells produce microvesicles containing
the SYT-SSX fusion gene, yet this research group was
unable to detect the biomarker in microvesicles or
PBMCs (peripheral blood mononuclear cell) obtained
from patient blood samples regardless of their metastatic
status [29]. In contrast, the SYT-SSX gene was detected
in peripheral blood in a case study of a single SS patient
who developed multiple lung metastasis 2 months after
local tumor resection from the thigh [30]. The presence
of circulating tumor cells (CTC) could be indicative of a
patient’s metastatic risk given their potential to extrava-
sate and form tumors in new locations [31], and CTC
abundance may account for discrepancies in SYT-SSX
detection abilities. CTCs can be readily isolated from pa-
tient blood by size exclusion, and CTC quantities vary
considerably among different SS patients [32].
Cinsarc signature genes
Gene expression profiling of soft tissue sarcomas re-
vealed a prognostic panel of 67 genes (CINSARC, com-
plexity index in sarcomas) with functional roles in
mitosis and chromosome management that are also
highly predictive of metastatic risk [33]. While many
CINSARC genes have been identified as molecular
markers associated with metastasis in other types of can-
cers, they are usually ascribed a proliferative function,
although they may actually have a greater role in
chromosome instability [33]. When the CINSARC classi-
fication criteria were used to stratify SS tumor speci-
mens into two prognostic groups, a highly significant
difference was observed in metastatic outcomes among
these patients [34]. However, since the CINSARC profile
emerged from an analysis of multiple types of soft tissue
sarcomas, these authors sought to determine if a better
metastatic prognostic profile could be developed for SS
[34]. Comparison of whole genome expression in 51
metastatic and 49 non-metastatic SS tumors revealed
significant upregulation of 59 genes in metastatic speci-
mens, 24% of which were common to the CINSARC
classification panel [34]. Importantly, singular expression
of the 2 most differentially regulated genes, CDCA2 (cell
division cycle A2) and KIF14 (kinesin family member
14), could better predict metastatic outcomes than the
overall CINSARC score in this patient cohort [34]. Func-
tionally, both of these genes code for proteins that help
to maintain chromosome integrity and are essential for
the completion of cytokinesis. KIF14 is localizes to the
central spindle during late phase mitosis and its inhib-
ition in tumor cells results in cell cycle arrest and the
formation of binucleated cells [35]. KIF14 was also
found to regulate adhesive components on the tumor
cell surface influencing migratory and invasive properties
that promote cell motility during metastasis [36].
CDCA2 has critical catalytic and structural functions
during late mitosis that help coordinate chromosome
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segregation and nuclear envelope reformation after div-
ision of nuclear contents [37].
IGFBP7
Insulin-like growth factor-binding protein-7 (IGFBP7,)
also termed IGFBP-related protein-1 (IGFBP-rP1), is a
secreted 31-kDa protein belonging to the IGFBP family
[38]. In various cancer types including hepatocellular
carcinoma [39], breast [40], brain [41], and colon [42],
IGFBP7 can function as a tumor suppressor and have
the ability to suppress proliferation, adhesion, angiogen-
esis, survival, or induce apoptosis and senescence [43–
45]. Yet the role of this protein in tumor behavior is
complex, as it undergoes extensive proteolytic process-
ing that reverses its cellular function and influence over
cell proliferation and adhesion activities [46]. In the
tumor stroma microenvironment, IGFBP7 expression is
closely related with the transforming growth factor beta
(TGF-β secretion [47], which is a potent factor promot-
ing tumor cell invasiveness and metastasis [48, 49].
TGF-β upregulates expression of IGFBP7 and angiogenic
capacity of tumor cells [50]. Recently, it was shown that
IGFBP7 expression in SS was higher that other types of
STSs and significantly associated with metastatic events
[51]. In addition, nuclear expression of another IGFBP
family protein, insulin like growth factor 1 receptor
(IGF1R),, was significantly related to poor survival in SS
patients who did not receive adjuvant chemotherapy
[52]. In sarcoma, IGF1R activation is known to activate
the phosphatidylinositol-3-kinase/serine/threonine kin-
ase Akt/Mammalian target of rapamycin (PI3K/Akt/
mTOR) pathway which promotes cancer progression
and metastasis [53]. These studies, highlight the po-
tential for proteins from the IGF family to be used as
prognostic biomarkers to help guide treatment deci-
sions in SS.
MMPs
The matrix metalloproteinases (MMPs), a family of zinc
and calcium dependent proteolytic enzymes, are in-
volved in the degradation extracellular matrix (ECM)
components and play key roles in tumor cell invasion
and metastasis [54]. Notably, the proteolytic activity of
MMPs can help release inactive TGFB in the extracellu-
lar space so that it can bind to its receptors and activate
downstream pathways such as PI3k/Akt and MAPK
which are critical to the epithelial mesenchymal transi-
tion (EMT) process underlying metastasis [55]. Benassi
et al. demonstrated that high levels of MMP2 and
MMP9 in biopsied tissue from patients with SS, was sig-
nificantly associated with metastasis (P = 0.008 and P =
0.005, respectively) [56]. In addition, lack of expression
the tissue inhibitors of metalloproteinases (TIMP) was
found to be a poor prognostic factor for disease-free
survival in synovial sarcoma (P = 0.009) [56]. The pro-
teolytic activity of MMPs and their activation process
can be inhibited by the TIMPs [57]. The presence of
TIMPs can suppress metastasis by preserving ECM in-
tegrity [58]. It has been shown that a decrease in TIMP-
1 correlated with a poor outcome in high-risk STS [59]
and colorectal cancer patients [60]. Both MMPs and
TIMPs can further be evaluated as biological markers
for predicting progression, metastasis and prognosis of
human SS.
Secernin-1
Secernin-1 (SCRN1), a 50-kDa cytosolic protein, is a
member of the secernin gene family that regulates exo-
cytosis in mast cells through a mechanism that has not
been well defined [61]. Exocytosis is a process by which
cells transport and release secretory products through
the cytoplasm to the cell membrane and several studies
have described that this promotes tumor growth, metas-
tasis and invasion [62, 63]. In colon cancer, SCRN1 ex-
pression promoted exocytosis secretion of MMP2 and
MMP, while silencing this gene reduced MMP2 secre-
tion, inhibited cell proliferation and decreased invasion
capability [63]. The poor prognostic significance of
SCRN1 expression in colon cancer [63, 64], is contrary
to that reported in synovial sarcoma [65]. A proteomics
analysis of tumor specimens collected from 13 SS pa-
tients, identified SCRN1 as positive prognostic factor
with significantly higher expression among patients who
were alive and disease free for at least 5 years [65]. Fur-
ther analysis of SCRN1 expression in 45 SS tumor speci-
mens revealed a 5-year survival rate was 77.6 and 21.8%
for patients with secernin-1 positive and negative pri-
mary tumors, respectively (p = 0.0015), and significantly
associated with metastatic outcomes [65]. Metastasis-
free survival was significantly higher (62.8% vs. 16.7%)
in the SS patient group with SCRN1 positive tumors
compared to that with SCRN1 negative tumors (p =
0.0012) [65].
EZH2
Enhancer of zeste homologue 2 (EZH2) is a member of
the polycomb group (PcG) protein family, which is com-
posed of epigenetic transcriptional regulators that par-
ticipate in cell cycle regulation, DNA damage repair, cell
differentiation, senescence, and apoptosis [66]. In cancer,
EZH2 expression is associated with a worse prognosis
and required for promotion of metastasis [67]. In SS,
overexpression of EZH2 helps to distinguish PDSS,
which is defined by high cellularity, high nuclear grade,
high mitotic activity and an agresssive clinical course
that tends to include early recurrence and metastasis,
from the MPSS and BPSS histological subtypes [68].
EZH2 overexpression in SS is correlated with high
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H3K27 trimethylation, which facilitates chromatin com-
paction and gene silencing [68]. Importantly, high ex-
pression of EZH2 is predictive of developing distant
metastasis even in the better-differentiated MPSS and
BPSS subtypes [68]. In a recent preclinical study, the
anti-tumor effect of EZH2 inhibition was evidenced in
human SS models in vitro, as well as xenograft and
patient-derived xenograft (PDX) models in vivo [69].
Moreover, Ramagila et al. found high EZH2 expression
to be correlated with metastatic disease in pediatric soft
tissue sarcomas [70]. Low expression of EZH2 restricts
cell proliferation and induces cell cycle arrest at the G2
phase, whereas the overexpression of EZH2 can shorten
the G1 phase of the cell cycle and lead to cell accumula-
tion in the S phase [71, 72]. Moore et al. showed that
EZH2 knockdown is sufficient to reduce distant metasta-
sis in vivo [73]. EZH2-specific inhibition is an active area
of researcher, with several human phase 1 and 2 trials
now underway, such as an ongoing phase II, multicenter
study of the EZH2 inhibitor tazemetostat in adult sub-
jects with INI1-negative tumors or relapsed/refractory
SS (https://clinicaltrials.gov/ct2/show/NCT02601950).
NY-ESO-1
New York esophageal squamous cell carcinoma 1 (NY-
ESO-1), encoded by the CTAG1B gene, is a 22 kD hydro-
phobic protein cancer-testis antigen [74]. NY-ESO-1 is
expressed in many cancers, associated with poor progno-
sis, and elevated metastatic risk [75]. The function of NY-
ESO-1 is still unknown, but is of particular interest to re-
searchers because it is highly immunogenic eliciting both
cellular and humoral responses, and a large number of
major histocompatibility complex (MHC) class I- and
class II-restricted NY-ESO-1 epitopes have been identified
[76]. Furthermore, NY-ESO-1 protein expression is signifi-
cantly higher in metastatic versus primary tumors [75, 77,
78]. NY-ESO-1 is an attractive target for SS treatment be-
cause chemotherapy has a limited durable efficacy in re-
lapsed or metastatic SS demonstrating the need for novel
more effective therapies. NY-ESO-1 is expressed in ap-
proximately 80% of patients with SS which could be useful
for distinguishing this cancer from other types of mesen-
chymal tumors, and identifying patients who would bene-
fit from NY-ESO-1 targeted therapies [79]. In a clinical
trial using genetically engineered T cells reactive with NY-
ESO-1 in patients with metastatic synovial cell sarcoma,
tumor regression was achieved in 67% of the patients [80].
Several clinical trials employing NY-ESO-1 are currently
under way in patients with SS (https://clinicaltrials.gov/
ct2/show/NCT01343043, NCT02609984).
CXCR4
Chemokine receptor 4 (CXCR4), is a 352-amino acid
seven-transmembrane G protein-coupled cell surface
receptor with an important role in homing of
hematopoietic stem cells and lymphocyte trafficking that
has been found to promote cell migration, invasion and
angiogenesis [52, 81]. The CXCR4 pathway has been
shown to be associated with tumor progression and poor
prognosis in many types of cancer including breast [82],
lung [83], colon [84], melanoma [85] and soft tissue sar-
comas [86]. CXCR4 promotes metastasis by activating
activating extracellular signal-regulated kinase 1/2
(ERK1/2), Akt/PKB and Nuclear factor-κB (NF-κB),
which increases the adhesion and invasive ability of can-
cer cells in part by the activity of MMP2 and MMP9
[87–89]. CXCR4 has a pivotal role in the migration of
cancer cells between the primary and the metastatic site
in synovial sarcoma [52, 90]. Tumor cells expressing
CXCR4 that detach from the primary tumor and enter
the circulatory system can migrate toward organs that
express its ligand CXCL12 [91]. Lung, lymph node, bone
marrow, and liver, the most frequent metastatic loca-
tions in SS [9], all express very high levels of CXCL12
[92]. A study of SS patients found that 5-year overall
survival (OS) rates were 47% for those with positive
CXCR4 staining, and 86% (P = 0.0003) for those with
negative CXCR4 staining [52]. A second study, reported
that 5 year survival outcomes for SS patients with posi-
tive CXCR4 staining was less than 30% [4]. Importantly,
it was found that SS cultures contain a subpopulation of
cells expressing high levels of CXCR4 that also express
high levels stem cell markers (NANOG, OCT4, SOX2),
and these cells have an increased tumor initiating cap-
acity in xenographic mouse models [4]. Although no
group has directly measured the metastatic risk of
CXCRX4 expression in SS, perhaps due to limited pa-
tient numbers, expression of this marker appears to be a
key factor both for cell migration and tumor propagation
at a distal site. Perhaps the use of CXCR4 antagonists,
many of which are already in various stages of clinical
development [93], and shown to significantly reduce
lung metastasis in mouse models of osteosarcoma [94],
would be a beneficial treatment option for patients with
metastatic SS, particularly in cases where tumors are
unresectable.
Conclusions
SS is a rare, aggressive subtype of soft tissue sarcoma. It
has a predilection for metastases to multiple organs, in-
cluding the lungs, lymph nodes, and bone. The ability of
this tumor to metastasize to multiple organs demon-
strates that the tumor can interact and invade multiple
environments. The overall prognosis is poor given the
high rate of metastatic disease and lack of effective
therapeutic agents. Nearly all mortality in patients with
SS is caused by metastatic disease, yet the biological
cause of these events has not been well characterized.
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The full transformation that occurs with the X;18
chromosomal translocation has not been completely elu-
cidated at this time. Several oncogenic biomarkers have
been found to be elevated in SS. As summarized in Fig. 1,
many of these biomarkers may be used to evaluate for
recurrence and metastatic disease and also help deter-
mine prognosis. The lack of the full understanding of
how the translocation and elevated biomarkers interact
with the host is a significant limitation in our ability to
effectively treat SS. Further research should be done to
help develop a greater understanding of these interac-
tions and the downstream effects that occur in SS, with
an emphasis on preventing metastatic disease. This will
not only enable patients to be monitored for progression
of disease and allow for counseling regarding prognosis,
but also be used to develop better treatments for this
subtype of soft tissue sarcoma.
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